Erhardt Leif R
Department of Clinical Sciences, Medicine, Lund University, Malmö University Hospital, Malmö, Sweden.
Vasc Health Risk Manag. 2007;3(6):985-97.
Incidence of cardiovascular (CV) and metabolic disease is increasing, in parallel with associated risk factors. These factors, such as low-density lipoprotein (LDL)-cholesterol, elevated blood pressure, obesity, and insulin resistance have a continuous, progressive impact on total CV risk, with higher levels and numbers of factors translating into greater risk. Evaluation of all known modifiable risk factors, to provide a detailed total CV disease (CVD) and metabolic risk-status profile is therefore necessary to ensure appropriate treatment of each factor within the context of a multifactorial, global approach to prevention of CVD and metabolic disease. Effective and well-tolerated pharmacotherapies are available for the treatment of risk-factors. Realization of the potential health and economic benefits of effective risk factor management requires improved risk factor screening, early and aggressive treatment, improved public health support (ie, education and guidelines), and appropriate therapeutic interventions based on current guidelines and accurate risk assessment. Patient compliance and persistence to available therapies is also necessary for successful modulation of CVD risk.
心血管（CV）疾病和代谢性疾病的发病率正在上升，同时相关风险因素也在增加。这些因素，如低密度脂蛋白（LDL）胆固醇、血压升高、肥胖和胰岛素抵抗，对总CV风险具有持续、渐进的影响，因素的水平越高、数量越多，风险就越大。因此，评估所有已知的可改变风险因素，以提供详细的总心血管疾病（CVD）和代谢风险状况概况，对于在预防CVD和代谢性疾病的多因素、整体方法背景下确保对每个因素进行适当治疗是必要的。有有效且耐受性良好的药物疗法可用于治疗风险因素。要实现有效风险因素管理的潜在健康和经济效益，需要改进风险因素筛查、早期积极治疗、改善公共卫生支持（即教育和指南），以及基于当前指南和准确风险评估的适当治疗干预措施。患者对现有疗法的依从性和持续性对于成功调节CVD风险也是必要的。
